WASHINGTON, DC (February 20, 2020) — “America looks to new generic drugs for significant savings on medicine, but our newest data show Medicare and commercial health plans delay their coverage. Delayed competition from generics increases costs for patients, taxpayers and employers and rewards the makers of high-priced brand-name drugs. Federal and state policymakers must act to ensure that America’s patients, as well as the overall health care system, realize the full promise of lower-priced generic competition.”
ATTRIBUTE TO: Craig Burton, Vice President, Policy
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.